MedTrace Logo

Taxotere Prostate Cancer New Indication Registration Trial in China

NCT00436839 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2012-07-09

No results posted yet for this study

Summary

To compare overall survival after receiving mitoxantrone and prednisone or docetaxel and prednisone in subjects with hormone-refractory metastatic prostate cancer.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Docetaxel

75mg/m² intravenously (day 1) every 21 days

DRUG

Mitoxantrone

12mg/m² intravenously every 21 days

DRUG

Prednisone

10mg orally given daily

Sponsors & Collaborators

Principal Investigators

  • Jing Fu · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436839 on ClinicalTrials.gov